Meanwhile, as the antagonist treatment inhibits endogenous glutamate signaling on mGluR2/3, the activity of this signaling pathway can be crucial for blood pressure regulation, and may become a pharmaceutical treatment target for patients with hypertension. Here, GRM2 is linked to hypertensive disorder.